Research programme: GPBAR1 protein agonists - Exelixis

Drug Profile

Research programme: GPBAR1 protein agonists - Exelixis

Alternative Names: TGR5 protein agonists - Exelixis; XL-475

Latest Information Update: 05 Jun 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Small molecules
  • Mechanism of Action GPBAR1 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Metabolic disorders

Most Recent Events

  • 05 Jun 2014 Discontinued - Preclinical for Metabolic disorders in USA (unspecified route)
  • 01 Aug 2013 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)
  • 13 Oct 2010 Exelixis grants Bristol-Myers Squibb an exclusive worldwide licence to its small molecule TGR5 agonist programme including back-up compounds subject to antitrust clearance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top